By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Leerink Swann today lowered its revenue and EPS estimates for Illumina from a week ago to reflect lost consumables sales on its older next-gen sequencing platforms and softer microarray consumables sales sequentially.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

In Science this week: caution urged in use of gene drives, and more.